)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
Dyne Therapeutics
Dyne Therapeutics (DYN) investor relations material
Dyne Therapeutics 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary15 Jan, 2026
Strategic vision and platform advancement
Advancing a clinically validated platform for rare neuromuscular diseases, with two late-stage assets in DMD and DM1 and near-term value drivers including BLA submission and product launches in 2026–2027.
FORCE platform enables targeted delivery to muscle and CNS using proprietary Fab against TfR1, supporting multiple payloads and broad pipeline expansion.
Human and non-human primate data show superior delivery and functional improvement, especially with DYNE-251 in DMD.
Cash position of ~$1.1 billion as of 12/31/25, with runway into Q1 2028 and all assets fully owned.
Platform enables capital-efficient expansion and de-risked pipeline, aiming to triple DMD market size.
Clinical pipeline and data highlights
DELIVER trial for DYNE-251 in DMD showed a seven-fold increase in dystrophin and significant functional improvements at six months, with robust results across TTR velocity, 10MWR, NSAA, SV95C, PUL2.0, and FVC %p.
Durable improvements maintained up to 36 months; safety profile favorable with most adverse events mild or moderate and over 1,000 doses administered.
DYNE-101 in DM1 demonstrated 33% DMPK knockdown, 25% splicing correction, and functional improvements in vHOT, sit-to-stand, 10-meter walk, and patient-reported outcomes through 12 months.
Quantitative muscle testing showed 10–20% strength increase; MDHI subscales indicated CNS impact at higher doses.
No serious related adverse events for DYNE-101; most TEAEs were mild or moderate, with 93 patient years and over 1,000 doses.
Regulatory and commercialization plans
Planned U.S. Accelerated Approval submission for DYNE-251 in DMD in Q2 2026, with potential commercial launch in Q1 2027.
DYNE-101 in DM1 targeting Accelerated Approval submission in early Q3 2027, with Phase 3 studies planned for global approval.
Breakthrough designation for both DMD and DM1, with ongoing FDA dialogue and alignment on accelerated approval pathways.
Commercial infrastructure, management, and supply chain in place for 2027 launch; gross margins expected to be competitive with rare disease antibody companies.
Well-characterized patient populations and concentrated treatment centers support efficient market entry and reimbursement.
How will Z-Rostudirsen redefine DMD treatment?
What specific CNS endpoints for DM1 Phase III?
How does platform validation accelerate pipeline?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Dyne Therapeutics earnings date
Q4 202527 Feb, 2026
Dyne Therapeutics
Next Dyne Therapeutics earnings date
Q4 202527 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Dyne Therapeutics Inc. is a biotechnology firm engaged in the development of innovative therapeutics aimed at addressing genetically driven muscle diseases. Established in 2017 and based in Waltham, Massachusetts, the company primarily focuses on advancing a portfolio of muscle disease therapeutics. These efforts include targeting conditions such as myotonic dystrophy type 1, duchenne muscular dystrophy, facioscapulohumeral dystrophy, and other rare skeletal, cardiac, and metabolic muscle diseases. Dyne Therapeutics utilizes its proprietary FORCE platform, which is designed to enhance the delivery of disease-modifying therapeutics directly to muscle tissue. Its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage